Spero Therapeutics (SPRO) Insider Trading & Ownership $1.03 -0.04 (-3.72%) (As of 12/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Spero Therapeutics (NASDAQ:SPRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.52%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$57,336.41 Get SPRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Spero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SPRO Insider Buying and Selling by Quarter Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Spero Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/27/2024Ankit MahadeviaDirectorSell5,912$1.35$7,981.20 8/27/2024Sath ShuklaCEOSell2,757$1.35$3,721.95 8/27/2024Timothy KeutzerCOOSell2,213$1.35$2,987.55 8/5/2024Sath ShuklaCEOSell17,641$1.31$23,109.71 8/2/2024Sath ShuklaCEOSell14,800$1.32$19,536.00 (Data available from 1/1/2013 forward) SPRO Insider Trading Activity - Frequently Asked Questions Who is on Spero Therapeutics's Insider Roster? The list of insiders at Spero Therapeutics includes Ankit Mahadevia, Aquilo Capital Management, Llc, Kamal Hamed, Sath Shukla, and Timothy Keutzer. Learn more on insiders at SPRO. What percentage of Spero Therapeutics stock is owned by insiders? 4.52% of Spero Therapeutics stock is owned by insiders. Learn more on SPRO's insider holdings. Which Spero Therapeutics insiders have been selling company stock? The following insiders have sold SPRO shares in the last 24 months: Ankit Mahadevia ($41,609.26), Kamal Hamed ($50,159.92), Sath Shukla ($69,171.88), and Timothy Keutzer ($11,636.43). How much insider selling is happening at Spero Therapeutics? Insiders have sold a total of 123,060 Spero Therapeutics shares in the last 24 months for a total of $172,577.49 sold. Spero Therapeutics Key ExecutivesDr. Ankit Mahadevia M.D. (Age 43)MBA, Co-Founder & Chairman of the Board Compensation: $1.39MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Compensation: $1.12MMr. Timothy Keutzer (Age 56)Chief Operating Officer Compensation: $938.57k1 recent tradesMs. Esther P. Rajavelu (Age 45)CFO, Chief Business Officer & Treasurer Mr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 63)M.D., M.P.H., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Fate Therapeutics Insider Trades Lexeo Therapeutics Insider Trades DiaMedica Therapeutics Insider Trades Zentalis Pharmaceuticals Insider Trades Atai Life Sciences Insider Trades Tenaya Therapeutics Insider Trades Aclaris Therapeutics Insider Trades Acrivon Therapeutics Insider Trades Inhibrx Insider Trades LifeVantage Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:SPRO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
